clonidine FDA Alerts
The FDA Alert(s) below may be specifically about clonidine or relate to a group or class of drugs which include clonidine.
MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Following is a list of possible medication recalls, market withdrawals, alerts and warnings. For the latest FDA MedWatch alerts, go here.
Recent FDA Alert(s) for clonidine
Implanted Pumps: Safety Communication - Use Caution When Selecting Pain Medicine for Intrathecal Administration
Nov 14, 2018
Audience: Patient, Caregiver, Health Professional, Pain Management, Pharmacy, Neurology, SurgeryISSUE: The FDA is aware that patients undergoing treatment or management of pain are commonly given pain medicines in the spinal fluid (intrathecal administration) that are not FDA approved for use with the implanted pump. While individual patients may experience some relief from using pain medicines not approved for intrathecal administration in their implanted pumps, such use may create additional risks including dosing errors, pump failures, and other safety concerns. The FDA wants to ensure that patients, caregivers, compounders, pharmacists, and health care providers are aware of these risks to make informed treatment decisions.
BACKGROUND: Implanted pumps are medical devices that are surgically implanted under the skin, typically in the abdomen. They are connected to an implanted catheter and are used to deliver prescription medicines and fluids within the body, including the intrathecal space (into the spinal fluid), to treat pain, muscle spasticity, and other diseases or conditions. Implanted pumps are periodically refilled with medicines or fluids by a health care provider.
They are often used to treat or manage pain after other treatments, such as oral medicines, physical therapy, or surgery, are unsuccessful.
The FDA-approved implanted pump labeling identifies which pain medicines are approved for use with each pump. Pain medicines approved by FDA for delivery into the spinal fluid must meet additional safety standards because the spinal cord and brain tissue are highly sensitive to preservatives or infectious organisms such as bacteria or viruses. The implanted pump’s current labeling should be reviewed to determine which pain medicines are approved for use in each pump. The table below includes examples of medicines approved and not approved for intrathecal use with implanted pumps to treat or manage pain.
RECOMMENDATION: When considering a medicine for use in an implanted pump:
Review the implanted pump labeling to identify the medicines and medicine concentrations approved for use with that specific pump.
Be aware that the following medicines are NOT currently approved for use with implanted pumps for intrathecal infusion of pain medications:
Any mixture of two or more different kinds of medicines
Any compounded medicine (for example, to achieve higher concentration or different formulation of an FDA approved medicine)
Be aware that while individual patients may experience some relief from using medicines not approved for intrathecal administration in their implanted pumps for pain management, such use may pose additional risks including pump failures, dosing errors, and other potential safety issues.
Health care providers, patients, and caregivers are encouraged to consider and discuss both the benefits and risks of using implanted pumps for the intrathecal infusion of medications for pain management in order to make informed treatment decisions.
Report adverse events to the FDA if you suspect an implanted pump is having problems:
User facilities must comply with the applicable Medical Device Reporting (MDR) regulations.
Health care providers employed by facilities that are subject to the FDA's user facility reporting requirements should follow the reporting procedures established by their facilities.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
Complete and submit the report Online: www.accessdata.fda.gov/scripts/medwatch/index.cfm
Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
[11/14/2018 - Medical Device Safety Communication - FDA]
Injectable drugs prepared by Urgent Care Pharmacy
Nov 18, 2002
Audience: All healthcare professionalsThe Food and Drug Administration (FDA) announced a nationwide alert concerning all injectable drugs prepared by Urgent Care Pharmacy of Spartanburg, South Carolina, based on the lack of assurance that their products are sterile. Non-sterility of injectable products can represent a serious hazard to health that could lead to life-threatening injuries and death. FDA inspection of Urgent Care's facility revealed the firm failed to have adequate controls to ensure necessary sterility, including the absence of appropriate testing for potency and sterility prior to distribution.
FDA is aware that Urgent Care has distributed the following injectable drugs to physicians, hospitals, clinics and consumers in Connecticut, Illinois, Indiana, Kentucky, Louisiana, Massachusetts, Mississippi, New Hampshire, North Carolina, South Carolina and Virginia: Baclofen, Betamethasone, Bimix 30:1, (Phentolamine mesylate/papaverine), Clonidine, Estradiol, Hydromorphone HCl, Fentanyl, methylprednisolone acetate, Morphine Sulfate/Bupivacaine, Papaverine HCl, Super Trimix (Papaverine HCl/phentolamine mesylate/prostaglandin), Testosterone cypionate, Testosterone/Estradiol.
[November 15, 2002 Talk Paper - FDA]
More clonidine Resources
- Clonidine Consumer Information
- Clonidine injection Consumer Information
- Clonidine transdermal Consumer Information
- Clonidine Extended-Release Tablets Consumer Information
- Clonidine Tablets Consumer Information
- Clonidine Epidural Injection Consumer Information
- Clonidine Patches Consumer Information
- Clonidine Epidural Advanced Consumer Information
- Clonidine Oral, Transdermal Advanced Consumer Information
- Clonidine Transdermal Advanced Consumer Information
- Clonidine AHFS DI Monograph
- Clonidine Prescribing Information
- Clonidine Extended Release Tablets Prescribing Information
- Clonidine Injection Prescribing Information
- Clonidine Patch Prescribing Information
- Clonidine Tablets Prescribing Information
- CloNIDine A-Z Drug Facts